Reflecting on progress and partnerships at Immutep

Reflecting on progress and partnerships at Immutep

 

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network


Source: Finance News Network

Share this post